FDA Approves the First and Only Peptide Powered Frown Line Treatment

How long does it last?

Daxxify lasts an average of six months and up to nine months for some patients. Other neuromodulators are indicated for around three months.

What areas can be treated?

Daxxify is FDA-approved for the on-label treatment of the glabellar lines commonly known as the 11’s or frown lines between the eyes. However, there are several off-label areas that Providers have been routinely treating for years with neuromodulators, such as forehead lines, crows feet, lines around the mouth, and lower face and neck.

There are also Therapeutic Indications for neuromodulators, such as migraine, TMJ, hyperhidrosis, etc.

What is Daxxify?

Daxxify is a unique peptide-powered formulation with a safety profile well established in the largest clinical trial ever conducted for frown line treatment. (Sakura 3 trial). Daxxify is a neuromodulator similar to Botox, Dysport, Xeomin, and Jeuveau. What sets Daxxify apart is the use of PXT (Peptide Exchange Technology) instead of human serum albumin as a stabilizer. PXT helps anchor the toxin to its target, enhancing internalization and maximizing efficiency.

How does Daxxify work?

Daxxify (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent. In simple terms, Daxxify works by temporarily blocking the signal, which causes muscles to contract. This action, in turn, softens dynamic wrinkles, i.e., frown lines. Daxxify starts working in a matter of hours to days and can take up to two weeks to peak.

Are there any side effects?

The most common side effects with Daxxify are swelling or bruising at the injection site and 6% of patients in the original trial reported a mild headache. Rarely, temporary eyelid drooping or facial paresis is possible if proper technique is not used or posttreatment instructions are not followed by the patient! This can occur with ANY neuromodulator!

How much does it cost?

Although Daxxify is similar to other neuromodulators, the dosing is not interchangeable and cannot be compared to any other neuromodulator, meaning pricing with Daxxify will look different than traditional neuromodulators. Because Daxxify lasts an average of six months, up to nine months in some patients, and provides a consistent result with only two treatments per year instead of four, expect to see a higher cost per treatment which averages out to around the same or even less annually than what patients are used to spending.